Literature DB >> 6635915

Incidence and significance of primary stones of the common bile duct in choledocholithiasis.

N J Lygidakis.   

Abstract

To assess the significance of primary common bile duct stones as an index predisposing to recurrent choledocholithiasis, 522 patients who underwent choledochotomy are presented in this study for further discussion. There was an association of primary common bile duct stones with bile infection, with an increased incidence of anaerobes in bile cultures and with an advanced inflammatory infiltration of the biliary tree. Furthermore, primary common bile duct stones have an increased incidence in patients with a long history of symptoms of the disease, of advanced age and who have had previous biliary surgical treatment. Primary stones are an index of existent biliary stasis and have to be taken into serious consideration in dealing with patients suffering from biliary lithiasis.

Entities:  

Mesh:

Year:  1983        PMID: 6635915

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  4 in total

1.  Epidemiological study on Korean gallstone disease: a nationwide cooperative study.

Authors:  M H Kim; B C Lim; S J Myung; S K Lee; H C Ohrr; Y T Kim; I H Roe; J H Kim; J B Chung; C D Kim; C S Shim; Y B Yun; Y I Min; U S Yang; J K Kang
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

2.  An angulated common bile duct predisposes to recurrent symptomatic bile duct stones after endoscopic stone extraction.

Authors:  D Keizman; M I Shalom; F M Konikoff
Journal:  Surg Endosc       Date:  2006-07-20       Impact factor: 4.584

3.  Anatomical variation of pancreatobiliary ducts in biliary stone diseases.

Authors:  Y Kubota; T Yamaguchi; K Tani; M Takaoka; K Fujimura; M Ogura; S Yamamoto; T Mizuno; K Inoue
Journal:  Abdom Imaging       Date:  1993

4.  The clinical significance of bile duct sludge: is it different from bile duct stones?

Authors:  D Keizman; M Ish-Shalom; F M Konikoff
Journal:  Surg Endosc       Date:  2007-03-07       Impact factor: 3.453

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.